@

Sciomics - About Us

The Power of Proteomics: Revolutionizing Science and Healthcare

Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients' quality of life by utilizing molecular signatures for accurate diagnosis and treatment. 

At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to improve treatment with Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling.

We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). Our microarray platform, scioDiscover, is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its reliable results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. Our team is dedicated to supporting you throughout every stage of your project. Whether you need guidance, have questions, or require full-scale project support, we are committed to ensuring your success: 

Biomarkers_in_Precision_Medicine.jpg

Project Planning: From planning to execution, we will help you navigate the most efficient route to achieve your research objectives. 

Technical Expertise: Our skilled team of professionals provides unmatched proficiency in your proteomic analysis endeavors.

Customized Solutions: We provide customized solutions to meet your specific research needs.  

Comprehensive Study Report: Our services include a comprehensive data analysis and a customized report to provide a complete picture of your medical sample.

 

Our Platform Is Used For:

• Protein Biomarker Identification and Verification

• Novel Drug Target Discovery

• Mode-of-Action Analysis

• Pathway Activity Analysis

• Disease Model Characterization, among other key applications 

 

Join us on our mission to revolutionize medicine. Together, we can reshape the future of healthcare.

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling

Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility       Our scioCD profiling service covers 260…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023)
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho